FTC antitrust charges against Impax dismissed
A judge has found it unlikely that Impax Laboratories would launch a generic drug before a final court decision in related patent litigation and has dismissed a case against the company.
Fed Circuit sides with district court in UCB win against generics
Pharmaceutical company UCB has emerged victorious in a case against major generic drug companies after its patent win was affirmed on appeal.
Boehringer seeks injunction in pig vaccine case
Animal health company Boehringer Ingelheim Vetmedica has sued Merck & Co and Merck Animal Health for infringing three patents covering vaccines for treating pig disease.
DowDuPont unit and Monsanto sign insect licensing deal
Corteva Agriscience, the agriculture division of DowDuPont, has signed a licensing deal with Monsanto to use its technology for fighting insects found on corn.
Lundbeck and Takeda take on Lupin over anti-depressant ANDA
Pharmaceutical companies Lundbeck and Takeda have sued generic drug producer Lupin for infringing a patent directed to anti-depressant medication Trintellix (vortioxetine hydrobromide).
UKIPO issues formal response to Industrial Strategy IP views
The UK Intellectual Property Office has published several proposals, including some addressing barriers to growth for IP-rich companies, in response to received views of IP with regard to the government’s Industrial Strategy.
FDA identifies companies ‘potentially blocking access’ to drug samples
The US Food and Drug Administration has published a list of companies that it suspects might be preventing generic drug producers accessing samples of branded products.
Federal Circuit affirms Praxair patent victory against Mallinckrodt
The US Court of Appeals for the Federal Circuit has affirmed a patent victory for industrial gases company Praxair against pharmaceutical business Mallinckrodt.
Novartis acquires gene therapy company
Novartis has acquired clinical-stage gene therapy company AveXis.
Pharmacies hit Allergan with Restasis competition claims
Four US pharmacies have filed an antitrust lawsuit against Allergan over the drug company’s “unlawful scheme” to maintain its patent monopoly over dry-eye treatment Restasis (cyclosporine ophthalmic emulsion).
